Synthesis of a Rhodium Carbonyl Phosphaalkenyl–Phosphido Complex: A Phosphorus Congener of Schiff Base Type N,N′-Chelating Monoanionic Ligands

A monoanionic, bidentate phosphaalkenyl–phosphido ligand was designed, synthesized, and used for the complexation of a rhodium carbonyl fragment. The characterization of the latter revealed delocalized π electrons on the phosphaalkenyl–phosphide moiety. The catalytic activity of this rhodium carbonyl complex has been demonstrated in a hydrosilylation reaction

Synthesis and Isolation of a Silylsilicate Containing Two Pentacoordinated Silicon Atoms by Monoprotonation of a Disilicate and Monodeprotonation of a Disilane

A silylsilicate, which is an intermediate in double protonation of a disilicate bearing two sets of a C,O-bidentate ligand at two pentacoordinated silicon atoms to give a disilane, was synthesized and isolated. The X-ray crystallographic analysis of both the silylsilicate and the disilane revealed intramolecular O···Si coordination, giving the silicon atoms pentacoordinated states. In the silylsilicate, the Si1–O2 and Si2–O3 bonds are almost in parallel. Deprotonation of the silylsilicate, which was also prepared by monodeprotonation of the disilane, gave the disilicate. The oxidation potential and UV/vis absorption maximum are both intermediate between those of the disilicate and the disilane, reflecting the changes in the charges

Synthesis of a Rhodium Carbonyl Phosphaalkenyl–Phosphido Complex: A Phosphorus Congener of Schiff Base Type N,N′-Chelating Monoanionic Ligands

A monoanionic, bidentate phosphaalkenyl–phosphido ligand was designed, synthesized, and used for the complexation of a rhodium carbonyl fragment. The characterization of the latter revealed delocalized π electrons on the phosphaalkenyl–phosphide moiety. The catalytic activity of this rhodium carbonyl complex has been demonstrated in a hydrosilylation reaction

Additional file 1 of Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy

Additional file 1: Figure S1. Chest CT images showing preexisting interstitial lung disease (ILD) and drug-induced ILD (DIILD) at the post-ICI setting. Each case number corresponds to that in Table S2. In case 11 (a man with non-small cell lung cancer), CT before initiation of docetaxel therapy following prior durvalumab monotherapy showed localized subpleural reticulation in the lower right lobe (a). CT at the onset of DIILD demonstrated new diffuse ground-glass opacity (GGO) (b). In case 12 (a man with bladder cancer), CT before initiation of enfortumab vedotin therapy following prior pembrolizumab monotherapy showed bilateral peripheral linear shadows with slight GGO (c). CT at the time of DIILD diagnosis showed extensive bilateral areas of GGO and airspace consolidation with traction bronchiectasis (d). In case 14 (a man with esophageal cancer), CT before initiation of docetaxel therapy following prior nivolumab monotherapy showed slight subpleural reticulation and GGO with interlobular septal thickening in the right lower lobe (e). CT image at the onset of DIILD demonstrated multifocal patchy alveolar opacities (f)